Physitrack Group
Investor Relations
Shaping the future of digital health by building value for key stakeholders through innovation and sustainable business management.
Recent reports and webcasts
Interim Report Q4
1st of October - 31st December 2025
From 2024 Annual Report
Key financial highlights
14
%
Year-on-year organic growth
€
1600
K
Total available liquidity
30
%
Operating cash flow (MSEK)
Physitrack Spotlight
Gain exclusive access to comprehensive insights that transcend conventional press releases through our Spotlight newsroom.
February 27, 2026
2025 Q4 CEO Interview
Details
Physitrack CEO comments on Q4 2025, North America, AI and Share Buyback program
